Skip to main content

Table 1 Genetic alterations of SMARCB1 in the AT/RT samples

From: NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors

Patient Copy number alteration Somatic mutation (type) aRelative expression level
P1 Heterozygous deletion c.811G > T
(stop codon, homozygote)
−3.76
P2 Homozygous deletion Not available −3.42
P3 Copy neutral c.118C > T
(stop codon, homozygote)
−2.22
P4 Heterozygous deletion c.93 + 2 T > C
(splice donor, heterozygote)
−2.51
  1. alog2-fold change of RPKM (sample to control)